Bridging the Gaps in Lung Cancer

Enriqueta Felip, MD, PhD, discusses selecting next-generation ROS1 TKIs after progression on crizotinib or entrectinib in NSCLC.

Luis Paz-Ares, MD, PhD, discusses protocols for managing T-cell engager and antibody-drug conjugate toxicities in lung cancer.

Tetsuya Mitsudomi, MD, PhD, discusses classifying and individualizing treatment for uncommon EGFR mutations in NSCLC.

Yang Xia, MD, PhD, discusses strategies for overcoming EGFR TKI resistance, including biomarker-selected and -unselected approaches.

Molly Li, MBBS, discusses selecting between HER2-directed TKIs and antibody-drug conjugates in first-line HER2-mutant NSCLC.

Lyudmila A. Bazhenova, MD, discusses the current state and future direction of antibody-drug conjugate development in lung cancer.

Narjust Florez, MD, discusses how the agenda for the Bridging the Gaps in Lung Cancer meeting evolves year to year based on emerging data and community feedback.

Noura Choudhury, MD, discusses how resistance mechanisms to tarlatamab-dlle could inform sequencing decisions in small cell lung cancer.

Jonathan Wesley Riess, MD, MS, discusses the evolving landscape of KRAS inhibitors, including the distinction between KRAS(OFF) and (ON) inhibitors.

Xiuning Le, MD, PhD, discusses treatment selection among targeted therapies for HER2-mutant NSCLC.

David Gerber, MD, discusses the evolution of ALK TKIs and the central nervous system toxicity tradeoffs seen with later-generation agents in NSCLC.

Jay M. Lee, MD, discusses the role of ctDNA in guiding surveillance and treatment escalation decisions in resected NSCLC.

Amy L. Cummings, MD, discusses patient selection for adjuvant immunotherapy in resectable non–small cell lung cancer.

Sandip Patel, MD, discusses key unmet needs and open questions surrounding EGFR-mutant NSCLC that has transformed to SCLC.

Alissa Cooper, MD, discusses evolving strategies for biomarker-driven patient selection with tarlatamab in small cell lung cancer.

Jyoti Malhotra, MD, MPH, discusses current knowledge of ADC efficacy in patients with NSCLC and brain metastases.

Fawzi F Abu Rous, MD, discusses evolving strategies for HER2 and MET testing in non–small cell lung cancer.

Balazs Halmos, MD, shares suggestions regarding patient selection for adjuvant therapy after neoadjuvant chemoimmunotherapy and surgery in NSCLC.

Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.

Ravi Salgia, MD, PhD, highlights biomarker-driven strategies in development for second-line small cell lung cancer management.

Edward S. Kim, MD, MBA, highlighted the distinct purpose of the Bridging the Gaps in Lung Cancer consensus meeting.

Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research.

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.

Jonathan Wesley Riess, MD, MS, discusses developments in the treatment of patients with NSCLC harboring ALK or ROS1 rearrangements.

Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.

Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.